CA2735653A1 - Method of treating atrial fibrillation - Google Patents

Method of treating atrial fibrillation Download PDF

Info

Publication number
CA2735653A1
CA2735653A1 CA2735653A CA2735653A CA2735653A1 CA 2735653 A1 CA2735653 A1 CA 2735653A1 CA 2735653 A CA2735653 A CA 2735653A CA 2735653 A CA2735653 A CA 2735653A CA 2735653 A1 CA2735653 A1 CA 2735653A1
Authority
CA
Canada
Prior art keywords
ranolazine
amiodarone
atrial
administered
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2735653A
Other languages
English (en)
French (fr)
Inventor
Charles Antzelevich
Alexander Burashnikov
John Shryock
Sridharan Rajamani
Luiz Belardinelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CA2735653A1 publication Critical patent/CA2735653A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2735653A 2008-09-04 2009-09-03 Method of treating atrial fibrillation Abandoned CA2735653A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9435908P 2008-09-04 2008-09-04
US61/094,359 2008-09-04
US10877608P 2008-10-27 2008-10-27
US61/108,776 2008-10-27
PCT/US2009/055924 WO2010028173A2 (en) 2008-09-04 2009-09-03 Method of treating atrial fibrillation

Publications (1)

Publication Number Publication Date
CA2735653A1 true CA2735653A1 (en) 2010-03-11

Family

ID=41421639

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2735653A Abandoned CA2735653A1 (en) 2008-09-04 2009-09-03 Method of treating atrial fibrillation

Country Status (5)

Country Link
US (1) US20100056536A1 (enExample)
EP (1) EP2337559A2 (enExample)
JP (1) JP2012502047A (enExample)
CA (1) CA2735653A1 (enExample)
WO (1) WO2010028173A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
HUE034911T2 (hu) 2009-07-27 2018-03-28 Gilead Sciences Inc Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
EP2588197B1 (en) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NO3175985T3 (enExample) 2011-07-01 2018-04-28
WO2014179764A1 (en) * 2013-05-03 2014-11-06 Gilead Sciences, Inc. Method of treating atrial fibrillation
WO2015095370A1 (en) 2013-12-19 2015-06-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
JP2019510752A (ja) 2016-03-04 2019-04-18 ギリアード サイエンシーズ， インコーポレイテッド オートタキシン阻害剤の組成物及び合剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
WO2000041688A1 (en) * 1999-01-11 2000-07-20 The Board Of Regents Of The University And Community College System Of Nevada Use of an amiodarone compound as antifungal agent
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678272A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases

Also Published As

Publication number Publication date
US20100056536A1 (en) 2010-03-04
EP2337559A2 (en) 2011-06-29
WO2010028173A3 (en) 2010-11-04
WO2010028173A2 (en) 2010-03-11
JP2012502047A (ja) 2012-01-26

Similar Documents

Publication Publication Date Title
US20100056536A1 (en) Method of treating atrial fibrillation
AU2010339753B2 (en) Method of treating atrial fibrillation
JP3253092B2 (ja) 梗塞後の死亡率を低下させるための抗不整脈化合物の使用
KR20110026422A (ko) 영구적 심방 세동의 예방을 위한 드로네다론
Doggrell Amiodarone-waxed and waned and waxed again
Singh Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction
WO2010015939A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack
Advani et al. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol
KR20100135814A (ko) 혈중 칼륨 수준의 조절을 위한 약제의 제조에 있어서의 드로네다론 또는 그의 제약상 허용가능한 염의 용도
KR20230024347A (ko) 급성 심방 세동의 치료를 위한 설카르딘 투여
JP2957618B2 (ja) アミオダロンと、ニトロ誘導体、特にイソソルビト二硝酸と、必要に応じてさらにβ―遮断薬とを含む心臓保護効果のある医薬組成物
O'keefe et al. Efficacy of nisoldipine combined with beta‐adrenergic‐blocking drugs in the treatment of chronic stable angina
CA2586918C (en) Use of ion channel modulating compounds for treating acute atrial fibrillation in a human
AU2014274638B2 (en) Method of treating atrial fibrillation
EP2387996A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation
HK1197535A (en) Method of treating atrial fibrillation
HK1170675B (en) Method of treating atrial fibrillation
HK1197535B (en) Method of treating atrial fibrillation
WO2014179764A1 (en) Method of treating atrial fibrillation
WO2011141888A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovacular hospitalizations or death or cardiovascular events in patients with permanent atrial fibrillation
MXPA98007436A (en) Use of antiarrhythmic compounds in the reduction of post-infa mortality
TW201529068A (zh) 決奈達隆（ｄｒｏｎｅｄａｒｏｎｅ）於製備用於預防心血管疾病住院或死亡之藥劑之用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140902

FZDE Dead

Effective date: 20160906